Clinical trials: Decompensated Cirrhosis of Liver
Cirrhosis
Rifaximin Reduces the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial
Cirrhotic patients are predisposed to intestinal dysmotility, bacterial overgrowth, and increased intestinal permeability all leading to an increase in bacterial translocation and increased endotoxemia.
- Trial name
- NCT02190357
- Testing
- Rifaximin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Changzheng Hospital
Liver Diseases, Liver Fibrosis
Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo
A post-treatment follow-up observational study for liver disease subjects with or without liver cirrhosis after receiving emricasan or placebo. Subjects must have been enrolled in a prior IDN-6556 study to be eligible.
- Conditions
- Liver Diseases, Liver Fibrosis, Liver Cirrhosis, NASH Fibrosis
- Trial name
- NCT03479125
- Testing
- Ultrasound
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Decompensated Cirrhosis
CirrhoCare in COVID-19: A Pilot, Remote, Home Monitoring Study in Advanced Cirrhosis
The COVID-19 outbreak has exposed many strengths and weaknesses of delivering healthcare, and we want to assess whether patients with advanced liver cirrhosis can be effectively monitored at home, to limit hospital visits and…
- Trial name
- NCT05045924
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust
Liver Cirrhosis
Stem Cell Transplantation in Cirrhotic Patients
Chronic liver disease end by liver cirrhosis and increases the risk of cancer development. Chronic liver disease in Egypt is recognized as a serious health problem affecting greater than (20 %) of the population, where the main…
- Trial name
- NCT02943889
- Testing
- Mesenchymal stem cell transplantation
- Volunteers
- 40 people
- Sponsor
- Assiut University
Caregivers
CAREGIVER: A Trial to Improve the Burden and Distress of Caring for Persons With Decompensated Cirrhosis
The goal of this study is to enroll caretakers of patients with decompensated cirrhosis to determine if written emotional disclosure or resilience training interventions reduce distress and burden among primary informal…
- Trial name
- NCT04205396
- Testing
- Written emotional disclosure, Resilience training, No treatment
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- University of Michigan
Decompensated Cirrhosis, Ascites
VSL#3 and Spontaneous Bacterial Peritonitis
Research question: Do oral probiotics in patients with cirrhosis and ascites reduce intestinal bacterial concentrations, ascitic bacterial DNA, SBP and bacteraemia compared to antibiotics or placebo? This study is designed to…
- Trial name
- NCT01701297
- Testing
- cotrimoxazole, VSL#3 active
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Cirrhosis, Liver
Combination of Autologous MSC and HSC Infusion in Patients With Decompensated Cirrhosis
Though the results of autologous CD34+ cell infusion and MSC in independent studies have shown promise, yet they are yet to reach the desired long term outcome.
- Trial name
- NCT04243681
- Testing
- CD 34 and MSC infusion, Standard of care for Cirrhosis management
- Where
- India
- Volunteers
- 5 people
- Sponsor
- Asian Institute of Gastroenterology, India
Acute Kidney Injury, Cirrhosis
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
This study tests whether a medication called droxidopa can help improve blood flow to the kidneys in people with liver cirrhosis who develop kidney problems while in the hospital.
- Conditions
- Acute Kidney Injury, Cirrhosis, Decompensated Cirrhosis of Liver
- Trial name
- DROP-AKI (NCT06937307)
- Testing
- Droxidopa capsules
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Giuseppe Cullaro, MD
Hepatitis, Hepatitis B, Chronic
Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis
This research study was conducted to compare the safety and effectiveness of the investigational medication, LdT (Telbivudine) versus Lamivudine, a drug currently approved by the US, European and Asian Health Authorities for the…
- Conditions
- Hepatitis, Hepatitis B, Chronic, Cirrhosis
- Trial name
- NCT00076336
- Testing
- Telbivudine, Lamivudine
- Where
- 28 sites in United States, Australia and 19 more
- Volunteers
- 232 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) with or without ribavirin (RBV) for 12 weeks in adults with…
- Trial name
- NCT02996682
- Testing
- SOF/VEL, RBV
- Where
- 33 sites in Japan
- Volunteers
- 102 people
- Sponsor
- Gilead Sciences
HCV Related Cirrhosis
To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis
In this prospective randomized trial, A Minimum of 300 consecutive patients of decompensated HCV (Hepatitis C Virus) related cirrhosis, presenting to the Institute of Liver and Biliary Sciences hospital will be included and those…
- Trial name
- NCT02464631
- Testing
- Sofosbuvir + Ribavirin 1, Sofosbuvir + Ribavirin 2, Sofosbuvir + Ribavirin 3
- Where
- India
- Volunteers
- 62 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cirrhosis
To Study and Compare the Clinical Course and Development of Organ Failure in Severe Acute Hepatitis Without Ascites, Non-cirrhotic and Cirrhotic Patients With Ascites [Acute on Chronic Liver Failure] and Acute Deterioration of Previously Decompensated Cirrhosis.
The study will be conducted on patients admitted to Department of Hepatology from MARCH 2015 to DECEMBER 2016 at ILBS, New Delhi.All patients presenting to ILBS fulfilling the inclusion criteria will be included in the study and…
- Trial name
- NCT02465619
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cirrhosis, Liver
Microbiome Translocation in Different Circulatory Compartments in Decompensated Cirrhosis
Acquired dysfunctional immunity in cirrhosis predisposes patients to frequent bacterial infections contributing to disease progression and may lead to the development of acute-on-chronic liver failure (ACLF).
- Trial name
- NCT04195724
- Testing
- mNGS for pathogen detection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Compensated Cirrhosis, Decompensated Cirrhosis
To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis
Diabetes prevalence is increasing among cirrhotics and use of OAD in cirrhotics is limited because of risk of hypoglycaemia and other adverse effects, therefore in this study we would be using OAD in the form of Sitagliptin or…
- Trial name
- NCT06147518
- Testing
- Metformin, Sitagliptin, Dapagliflozin
- Where
- India
- Volunteers
- 240 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Cirrhosis, Diabetes Mellitus
Relationships Between Mean Plasma Glucose and HbA1c in Cirrhotic Patients With Hepatogenous Diabetes
The liver plays a crucial role in physiological glycemic control through its involvement in several glucose metabolism processes, including glycogenogenesis and glycogenolysis.
- Trial name
- NCT02325622
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Yonsei University
Liver Cirrhoses
Concordance Between Echocardiographic Assessment Performed in the Initial Phase of Decompensated Cirrhosis With Edema and Ascites by an Expert Intensive Care Physician and a Non-expert Gastroenterologist
The investigators hypothesize that trans-thoracic ultrasound performed by non-specialist gastroenterologists with a standard training by intensive care doctors will give equivalent results to those achieved by experts for a…
- Trial name
- EchoCirrho (NCT03650660)
- Testing
- Trans-thoracic ultrasound
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Liver Cirrhosis
Evaluation of Albumin and Midodrine Versus Albumin Alone in Outcome of Refractory Ascites in Patients With Decompensated Cirrhosis.
The project is about evaluation of albumin and midodrine versus albumin alone in outcome of refractory ascites in patients with decompensated cirrhosis. Cirrhosis is a leading cause of disability and mortality worldwide.
- Trial name
- NCT04816240
- Testing
- Midodrine, Albumin, Standard Medical Treatment
- Where
- India
- Volunteers
- 200 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Decompensated Cirrhosis of Liver
GCSF Therapy in Decompensated Cirrhosis - A Double Blinded RCT
Cirrhosis of liver is a leading cause of morbidity and mortality worldwide. Complications like ascites, spontaneous bacterial peritonitis, variceal bleed, hepatic encephalopathy, hepatorenal syndrome (HRS) and hepatocellular…
- Trial name
- NCT03911037
- Testing
- G-CSF
- Where
- India
- Volunteers
- 70 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Liver Cirrhosis
Subclinical Diabetes Confirmed by 75gm-OGTT Influence on the Prognosis of Decompensated Cirrhosis
Disorders of glucose metabolism, such as impaired glucose intolerance (IGT) and diabetes mellitus (DM), frequently occur in cirrhosis. However, it has been underestimated when fasting plasma glucose (FPG) levels are considered.
- Trial name
- NCT04828512
- Volunteers
- 1,015 people
- Sponsor
- Yonsei University
Decompensated Cirrhosis and Ascites
Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites
The goal of this clinical biomarker validation trial is to test the effect of a predictive biomarker panel to human albumin infusions in patients with liver cirrhosis and ascites.
- Trial name
- NCT05056220
- Testing
- Human albumin, sodium chloride
- Where
- 12 sites in Belgium, Denmark and 5 more
- Volunteers
- 240 people
- Sponsor
- Aleksander Krag